EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE
Compositions comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle are provided. Methods of treating an inflammatory disorder and methods of treating a cancer are further provided and include administering an effective amount of a composition comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle to a subject. Further provided are methods of diagnosing a colon cancer that include the steps of administering an edible plant-derived microvesicle incorporating a detectable label to a subject and then determining an amount of the detectable label in an intestine of the subject.
1 . A composition, comprising a therapeutic agent encapsulated by a microvesicle, wherein the microvesicle is derived from an edible plant.
2 . The composition of claim 1 , wherein the edible plant is a fruit.
3 . The composition of claim 1 , wherein the fruit is selected from a grape, a grapefruit, and a tomato.
4 . The composition of claim 1 , wherein the therapeutic agent is selected from a phytochemical agent, a stat3 inhibitor, and a chemotherapeutic agent.
5 . The composition of claim 4 , wherein the therapeutic agent is a phytochemical agent, and wherein the phytochemical agent is selected from curcumin, resveratrol, baicalein, equol, fisetin, and quercetin.
6 . The composition of claim 4 , wherein the therapeutic agent is a stat3 inhibitor, and wherein the stat3 inhibitor is JSI-124.
7 . The composition of claim 4 , wherein the therapeutic agent is a chemotherapeutic agent, and wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol.
8 . The composition of claim 1 , wherein the therapeutic agent comprises a nucleic acid molecule selected from an siRNA, a microRNA, and a mammalian expression vector.
9 . A pharmaceutical composition, comprising a composition according to claim 1 and a pharmaceutically-acceptable vehicle, carrier, or excipient.
10 . A method for treating an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a composition including a therapeutic agent encapsulated by a microvesicle, wherein the microvesicle is derived from an edible plant.
11 . The method of claim 10 , wherein the inflammatory disorder is selected from the group consisting of sepsis, septic shock, colitis, colon cancer, and arthritis.
12 . The method of claim 10 , wherein the composition is administered orally or intransally.
13 . The method of claim 10 , wherein administering the composition reduces an amount of an inflammatory cytokine in a subject.
14 . The method of claim 13 , wherein the inflammatory cytokine is selected from the group consisting of tumor necrosis factor-α, interleukin-1β, interferon γ, and interleukin-6.
15 . The method of claim 10 , wherein the edible plant is a fruit.
16 . The method of claim 15 , wherein the fruit is selected from a grape, a grapefruit, and a tomato.
17 . The method of claim 10 , wherein the therapeutic agent is a phytochemical agent.
18 . The method of claim 17 , wherein the phytochemical agent is curcumin.
19 . The method of claim 10 , wherein the inflammatory disorder is colitis.
20 . The method of claim 19 , wherein administering the composition increases an amount of intestinal epithelial cell proliferation in a subject.
21 . The method of claim 19 , wherein administering the composition increases an amount of Wnt-β-catenin signaling in the intestine of a subject.
22 . A method for treating a cancer in a subject, comprising administering to a subject an effective amount of a composition including a therapeutic agent encapsulated by a microvesicle, wherein the microvesicle is derived from an edible plant.
23 . The method of claim 22 , wherein the therapeutic agent is selected from a phytochemical agent, a stat3 inhibitor, and a chemotherapeutic agent.
24 . The method of claim 22 , wherein the cancer is selected from a brain cancer, a breast cancer, a lung cancer, and a colon cancer.
25 . The method of claim 22 , wherein the cancer is a brain cancer, and wherein the brain cancer comprises a glioma.
26 . The method of claim 22 , wherein the microvesicle comprises a cancer targeting moiety for directing the composition to a cancer cell.
27 . The method of claim 26 , wherein the cancer targeting moiety comprises folic acid.
28 . A method for diagnosing a colon cancer in a subject, comprising:
administering to a subject an effective amount of a composition including a microvesicle incorporating a detectable label, the microvesicle being derived from an edible plant;
determining an amount of the detectable label in an intestine of the subject; and
comparing the amount of the detectable label, if present, to a control level of the detectable label, wherein the subject is diagnosed as having colon cancer or a risk thereof if there is a measurable difference in the amount of the detectable label as compared to the control level.
29 . The method of claim 28 , wherein the subject has colon cancer.
30 . The method of claim 28 , further comprising selecting a treatment or modifying a treatment for the colon cancer based on the determined amount of the detectable label.
31 . The method of claim 28 , wherein the detectable label comprises a radioisotope or a fluorescent probe.
32 . The method of claim 28 , wherein the edible plant is a fruit,
33 . The method of claim 32 , wherein the fruit is selected from a grape, a grapefruit, and a tomato.
34 . The method of claim 28 , wherein administering the composition to the subject comprises orally administering the composition to the subject.